Castle Biosciences
CSTL
32.86
-0.55
-1.63%
Castle Biosciences
US · CSTL
#3242 by market cap
Listed 2019
32.86
-0.55
-1.63%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 5.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 86.41% -5.61pp
- Institutions
- 226 +6
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund59.04%
Hedge Fund20.59%
Public Company3.81%
Individual/Insider1.85%
Government Pension Fund1.08%
Private Company0.91%
Insurance Company0.73%
Sovereign Wealth Fund0.20%
Other11.75%
Top holders as of 2026-09-30
BlackRock
11.21% · 3.45M sh
RTW Investments, LP
9.02% · 2.78M sh
Principal Global Investors, LLC
4.87% · 1.50M sh
Vanguard Capital Management, LLC
4.02% · 1.24M sh
Acadian Asset Management LLC
2.86% · 881.86K sh
Allianz Asset Management AG
2.85% · 879.26K sh
Summit Partners Public Asset Management, LLC
2.68% · 824.87K sh
State Street Global Advisors
2.61% · 804.68K sh
Geode Capital Management, LLC
2.58% · 793.90K sh
Vanguard Portfolio Management, LLC
2.33% · 716.67K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 5 buys · 45 sells
| Name | Role | Stake |
|---|---|---|
| Derek Maetzold | Chief Executive Officer | 0.51% |
| Kristen Oelschlager | Chief Operating Officer | 0.28% |
| Ellen Goldberg | Independent Director | 0.13% |
| Tiffany Olson | Independent Director | 0.13% |
| Tobin Juvenal | Chief Commercial Officer | 0.13% |
| Kimberlee Caple | Independent Director | 0.12% |
| Daniel Bradbury | Independent Chairperson | 0.12% |
| Miles Harrison | Independent Director | 0.12% |
| Frank Stokes | Chief Financial Officer | 0.11% |
| Rodney Cotton | Independent Director | 0.11% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Tobin Juvenal | Chief Commercial Officer | Automatic Disposition | -6,116 | $32.67–35.04 |
| 2026-11-10 | Tobin Juvenal | Chief Commercial Officer | Derivative Exercise and Sale | -3,195 | $29.50–35.07 |
| 2026-11-01 | Derek Maetzold | Chief Executive Officer | Automatic Disposition | -14,496 | $36.01–36.81 |
| 2026-10-27 | Tobin Juvenal | Chief Commercial Officer | Automatic Disposition | -6,578 | $35.58–36.62 |
| 2026-10-25 | Tobin Juvenal | Chief Commercial Officer | Automatic Disposition | -3,288 | $33.08 |
| 2026-10-18 | Derek Maetzold | Chief Executive Officer | Automatic Disposition | -14,496 | $31.91 |
| 2026-10-11 | Tobin Juvenal | Chief Commercial Officer | Automatic Disposition | -3,288 | $33.64 |
| 2026-10-04 | Derek Maetzold | Chief Executive Officer | Automatic Disposition | -6,331 | $35.57 |
| 2026-10-04 | Derek Maetzold | Chief Executive Officer | Intent to Sell (Form 144) | -28,992 | $36.65 |
| 2026-10-04 | Derek Maetzold | Chief Executive Officer | Derivative Exercise and Sale | -8,165 | $2.39–35.57 |
| 2026-09-30 | Kristen Oelschlager | Chief Operating Officer | Derivative Exercise and Sale | -4,153 | $3.38–36.38 |
| 2026-09-29 | Tobin Juvenal | Chief Commercial Officer | Automatic Disposition | -6,577 | $34.20–35.50 |
| 2026-09-20 | Derek Maetzold | Chief Executive Officer | Automatic Disposition | -5,916 | $35.33 |
| 2026-09-20 | Derek Maetzold | Chief Executive Officer | Derivative Exercise and Sale | -8,580 | $2.39–35.33 |
| 2026-09-14 | Tobin Juvenal | Chief Commercial Officer | Automatic Disposition | -6,600 | $32.32–35.14 |
| 2026-09-10 | Derek Maetzold | Chief Executive Officer | Automatic Disposition | -5,934 | $32.00–32.78 |
| 2026-09-10 | Derek Maetzold | Chief Executive Officer | Derivative Exercise and Sale | -8,584 | $2.39–32.00 |
| 2026-08-31 | Kristen Oelschlager | Chief Operating Officer | Derivative Exercise and Sale | -4,152 | $3.38–34.02 |
| 2026-08-30 | Tobin Juvenal | Chief Commercial Officer | Automatic Disposition | -1,730 | $32.81 |
| 2026-08-27 | Derek Maetzold | Chief Executive Officer | Automatic Disposition | -6,132 | $33.14–33.88 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Castle Biosciences discussion 0 comments